Jubilant Life Sciences

Signs agreement with US biomedical dept

Jubilant Ingrevia on Wednesday said its subsidiary Jubilant Life Sciences International Pte Ltd has divested its 10 per cent stake in Safe Foods Corporation for a consideration of $18.2 million

The shares of the firm were listed on the bourses on March 19 in the list of T Group of Securities

In this quarter, Jhunjhunwala booked profit in information technology (IT) firm Firstsource Solutions (FSL) and raised his stake in pharmaceutical firm Jubilant Life Sciences

Drug firm Jubilant Life Sciences on Wednesday reported a 10.13 per centdecline in its consolidated net profit to Rs 224.12 crore for the quarter ended September,mainly on account of higher taxes. The company had posted a net profit of Rs 249.39 crore for the correspondingperiod of the previous fiscal, Jubilant Life Sciences said in a BSE filing. Total revenue from operations stood at Rs 2,374.89 crore for the quarter under consideration. It was Rs 2,265.93 crore for the same period a year ago, it added. Tax expense of the company for the quarter was Rs 89.55 crore as against Rs 42.84 crore for the same period of the previous fiscal, the filing said. "Q2'FY21 has witnessed a substantial improvement over the previous quarter despite continued adverse impact of the COVID-19 pandemic in at least the first half of Q2,"Jubilant Life SciencesChairmanShyam S Bhartia andCo-Chairman & MD Hari S Bhartia said. With the strong demand recovery and new business sign-ups, "we expect strong ...

The management said the company is witnessing strong demand conditions and improved pricing environment

Growth pickup and lower debt could improve its valuations

Barring unforeseen circumstances, the management expects strong performance in their Pharma, Life Science Ingredients, and Drug Discovery and Development Solutions business

Consolidated total revenue from the operations of the company stood at Rs 1,892.92 crore for the quarter under consideration. It was Rs 2,181.86 crore for the same period a year ago

All that happened in the markets today

Nifty's momentum indicators and oscillators on the weekly scales are still in 'buy' mode

Drug firm Jubilant Life Sciences is focused on sustaining its operational and financial performance in the near-term in the current scenario

The drug is being made available to over 1,000 hospitals providing Covid-19 treatment in India through the company's distribution network

The company said it has launched the generic version of antiviral drug remdesivir in India.

The injectable drug, under the brand name 'JUBI-R', is priced at Rs 4,700 per vial of 100 mg

These companies reported an increase in revenue and/or profit before tax for the March quarter

Life sciences, pharma segments offer investors value-unlocking opportunities

The stock hit a 52-week high of Rs 646, up 8% today, surpassing its previous high of Rs 639, touched on January 23, 2020, on the BSE.

Jubilant Life Sciences reported 92 per cent year on year (YoY) jump in normalised profit after tax at Rs 260 crore in Q4FY20. Ebitda margin also improved to 23.7 per cent from 16.3 per cent in Q4FY19.

The USFDA granted remdesivir an emergency use authorization for the treatment of hospitalized patients with severe Covid-19